Award

National Cancer Institute 3R01CA274967-04S1

Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer

Recipient

Icahn School of Medicine at Mount Sinai

Award Amount

$135,585.00

Ceiling

$135,585.00

Awarded

June 03, 2026

Identifier

3R01CA274967-04S1

Award for research on DDR-deficient lethal prostate cancer focusing on BRCA2 gene alterations and development of targeted therapies such as PSMA radiotherapy and CAR T-cell therapy.

Description

This project aims to investigate the role of DDR gene alterations in prostate cancer, with a focus on BRCA2, and develop targeted therapies including PSMA radiotherapy and CAR T-cell therapy.

View original record